J. Lutzky

发表

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

R. Sullivan, J. Kirkwood, S. Patel, 2016, Journal of Immunotherapy for Cancer.

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

G. Daniels, D. Rischin, A. Haydon, 2021, Annals of Oncology.

1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA.

J. Nemunaitis, G. Daniels, H. Kaufman, 2014, Annals of Oncology.